ASPIRE Trial Explores Early Chemotherapy Addition for Advanced Prostate Cancer
/in Clinical Trial, Metastatic, Phase 3/by MaxPhase 1 Trial: 161Tb-PSMA Offers Hope After Lutetium Failure in mCRPC
/in Clinical Trial, Metastatic/by MaxEfficacy and Safety of Combination ARSI, Denosumab, and Local Radiotherapy in Poly-Metastatic Prostate Cancer
/in Clinical Trial, Metastatic, Phase 2/by MaxAZD6621: A T-Cell Therapy Targets Hidden Prostate Cancer Driver
/in Clinical Trial, Metastatic, Phase 1, Phase 2/by MaxPhase 1/2: Tulmimetostat + ARPI Combo for mHSPC
/in Clinical Trial, Metastatic, Phase 1, Phase 2/by MaxPhase 2 Trial for Sacituzumab Tirumotecan and Tagitanlimab Combo
/in Clinical Trial, Metastatic, Phase 2/by MaxTJ101 Enters Testing for Advanced Prostate Cancer Patients
/in Clinical Trial, Metastatic, Phase 1/by MaxOST-504: A Novel Immunotherapy Targeting Prostate Cancer
/in Clinical Trial, Metastatic, Phase 1/by MaxProject Navigator
Let's try to finance it!
A new, user friendly way, to get information about current clinical trials available to prostate cancer patients.
Tags
177Lu-PSMA-617 abiraterone abiraterone acetate ADC ADT AI ai in healthcare antibody-drug conjugate apalutamide ATM B7-H3 bispecific antibody bone metastases bone metastasis BRCA BRCA2 cancer immunotherapy CAR-T CD3 clinical trial crispr darolutamide docetaxel drug repurposing drug resistance enzalutamide EZH2 inhibitor HRR immunotherapy mcrpc metastatic hormone-sensitive prostate cancer mHSPC mRNA NEPC neuroendocrine prostate cancer oncolytic virus PARP inhibitor Pluvicto prostate cancer protac PSMA radioligand therapy radiopharmaceuticals real-world data T-cell therapy
Latest Posts
- Not All Patients Benefit Equally: New Score Refines Cabazitaxel Use April 25, 2026
- B7‑H3 Expression Shapes Prognosis Differently Across Prostate Cancer Stages April 24, 2026
- DNA Smart Drugs: Precision Cancer Treatment With a Double Lock April 22, 2026
- Double-Masked PSMA-TCE JANX014 Enters Phase 1 for mCRPC April 21, 2026